Loss of RBM-26 causes mitochondria dysfunction in PLM. by Tamjid A. Chowdhury (14149846)

RBM-26 is expressed in the PLM and functions within neurons to protect against axon degeneration and prevent axon overlap defects. by Tamjid A. Chowdhury (14149846)

Mutations in <i>rbm-26</i> cause axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-... by Jinho Lee (587173)

Subjects:

Proportion of stillbirths in Stockholm among twin and singleton pregnancies. by Matilda Varli Hjärne (22766125)

Mediation effect of muscle strength on the associations of obesity with incidence of knee OA. by Laijun Yan (19797455)

Loss of RBM-26 function causes a reduction in the density of mitochondria in the PLM axon. by Tamjid A. Chowdhury (14149846)

HBV RNaseH inhibitors effects on capsid accumulation occur independent of HBV DNA synthesis. by Daniel P. Bradley (10306893)

Co-transformed cells grow preferentially as tumors in peritoneal cavities. by Mitchell Hayes (5334887)

Expression of RBM-26 is disrupted by P80L and L13V missense mutations. by Tamjid A. Chowdhury (14149846)

Effects of 1466 on capsid and pgRNA encapsidation compared to known CAM-A and CAM-E inhibitors. by Daniel P. Bradley (10306893)

Screening HBV RNaseH inhibitors in HepDES19 cell for effects on capsids and core protein. by Daniel P. Bradley (10306893)

1466 inhibits capsid accumulation independent of HBV replication. by Daniel P. Bradley (10306893)

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. …”

Forest Plot of Multivariate Odds Ratios for Risk Factors Associated with Nerve Injury 90 Days After Total Knee Arthroplasty. by Rahul H. Jayaram (21463899)

Subjects:

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

Subjects:

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

Subjects:

Relative frequency of type I (dark gray) and type II (light gray) errors in 10 000 replicas for each initial condition of the simulation. by Farrokh Habibzadeh (12256529)

Subjects:

PVS_ratio changes, ΔPVS_ratio, for different radiation doses within each treatment period: 0M–3M(a), 3M–12M(b), and 12M–FollowUp(c). by Ruitian Song (11045127)

Subjects:

Patient demographic information at four time points. by Ruitian Song (11045127)

Subjects: